Business
ImmuCell Announces a 28.4% Increase in Product Sales in Q1 of 2026, based on Preliminary, Unaudited Sales Results
PORTLAND, Maine, April 08, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that
About this update from Immucell Corporation
[{"type":"text","content":"PORTLAND, Maine, April 08, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops, manufactures and markets products to improve calf health and productivity, today announced preliminary, unaudited sales results for the first quarter of 2026. Total sales for the three-month period ended March 31, 2026 were $10.4 million, a 28.4% increase compared to the three-month period ended March 31, 2025. For the three-month period ended March 31: Domestic sales were $9.7 million in 2026, a 35.7% increase compared to 2025International sales were $0.6 million in 2026, a 30.2% decline compared to 2025Tri-Shield® sales were $7.9 million in 2026, a 38.5% increase compared to 2025Dual Force® & Other sales were $2.5 million in 2026, a 4.4% increase compared to 2025 “We had outstanding first quarter sales performance driven by our Tri-Shield® product,” commented Olivier te Boekhorst, President and CEO. “This gives us confidence that our strategy of focusing on First Defense® is working. We entered the year targeting growth and market share gains in scours solutions, and our team was well-prepared to meet demand during our peak season with new inventory and manufacturing strategies in place.” “First quarter results were driven by seasonal demand from the cow-calf segment that is typically less price sensitive and seeks the broadest protection. This plays to the strengths of Tri-Shield® and explains why November through February is our peak selling season,” explained Timothy C. Fiori, Chief Financial Officer of ImmuCell. “Our previous backorder situation continues to create challenges with predicting and explaining growth rates in 2026, however this quarter’s results indicate we are on the right track operationally.” Bobbi Jo Brockmann, Senior Vice President, Sales and Marketing of ImmuCell explained, “As we move into the second and third quarters, demand shifts toward our year-round dairy customers. We are focused on new customer acquisition within that segment, supported by the expansion of our commercial team. We are pleased to announce we have hired a leader for our international commercial efforts and two domestic field sales managers to support our growth.” Preliminary, Unaudited Sales ResultsDuring the Three-Month Periods Ended March 31,20262025$ Increase($ D...